Next 10 |
home / stock / holx / holx articles
Hologic (NASDAQ:HOLX) has outperformed the market over the past 20 years by 6.31% on an annualized basis producing an average annual return of 14.8...
Stephens initiated coverage on Hologic Inc (NASDAQ:HOLX), citing it as a major player in women’s health, known for its consistent revenue gro...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrade...
The Medical Instruments industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to it...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Hologic, Inc. (NASDAQ:HOLX) reported better-than-expected first-quarter financial results after the bell Thursday. Here's a look at the highli...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlett Packard Enterprise ...
Stocks rallied on Friday, reversing the negative session from Thursday, which had broken the longest winning streak in over two years, following ha...
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...